Latest Advances in Endothelial Progenitor Cell-Derived Extracellular Vesicles Translation to the Clinic


Posted: 2021-10-21 19:00:00
Review Front Cardiovasc Med . 2021 Oct 4;8:734562. doi: 10.3389/fcvm.2021.734562. eCollection 2021. Affiliations Expand Affiliations 1 Division of Regenerative Medicine, Department of Center for Clinical and Translational Science, Shonan Kamakura General Hospital, Kamakura, Japan. 2 Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura, Japan. 3 Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan. 4 Department of Software Engineering, Kazakh National Technical University After K.I. Satpayev, Almaty, Kazakhstan. Item in Clipboard Review Amankeldi A Salybekov et al. Front Cardiovasc Med. 2021. Show details Display options Display options Format Front Cardiovasc Med . 2021 Oct 4;8:734562. doi: 10.3389/fcvm.2021.734562. eCollection 2021. Affiliations 1 Division of Regenerative Medicine, Department of Center for Clinical and Translational Science, Shonan Kamakura General Hospital, Kamakura, Japan. 2 Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura, Japan. 3 Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan. 4 Department of Software Engineering, Kazakh National Technical University After K.I. Satpayev, Almaty, Kazakhstan. Item in Clipboard CiteDisplay options Display options Format Abstract Almost all nucleated cells secrete extracellular vesicles (EVs) that are heterogeneous spheroid patterned or round shape particles ranging from 30 to 200 nm in size. Recent preclinical and clinical studies have shown that endothelial progenitor cell-derived EVs (EPC-EVs) have a beneficial therapeutic effect in various diseases, including cardiovascular diseases and kidney, and lung disorders. Moreover, some animal studies have shown that EPC-EVs selectively accumulate at the injury site with a specific mechanism of binding along with angiogenic and restorative effects that are superior to those of their ancestors. This review article highlights current advances in the biogenesis, delivery route, and long-term storage methods of EPC-EVs and their favorable effects such as anti-inflammatory, angiogenic, and tissue protection in various diseases. Finally, we review the possibility of therapeutic application of EPC-EVs in the clinic. Keywords: clinical application of EPC exosomes; endothelial progenitor cells; exosomes; extracellular vesicles; miR (microRNA). Copyright © 2021 Salybekov, Kunikeyev, Kobayashi and Asahara. Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publication types [x] Cite Copy Format: Send To [x]

参考サイト PubMed: exsome



バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
6月 01, 2021 バイオアソシエイツ

Cardea Bio社、エクソソームとEVの検出技術「EV-Chip」を開発。リキッドバイオプシーをリアルタイムで分析する新世代のポータブルデバイスを目指す

分子生物学と半導体エレクトロニクスを統合するTech+Bio企業である米国のCardea Bio社は、同社の最高科学責任者であるキアナ・アラン博士と共同研究者が、「生物学的に活性化されたグラフェン・トランジスタによる年齢別循環エクソソームの迅速かつ電子的な識別と定量化( Rapid and Electronic Identification and Quantification of Age-Specific Circulating Exosomes via Biologically Activated…

ゲスト 949人 と メンバー 7人 がオンラインです